Lenvanamo contains Lenvatinib, an oral multikinase inhibitor used primarily for the treatment of thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma. Lenvatinib works by blocking tumor growth and angiogenesis, helping to slow cancer progression. It is usually prescribed in patients with advanced or unresectable cancers.

Mechanism of Action

• Lenvatinib inhibits multiple tyrosine kinases, including:

  • VEGFR1, VEGFR2, VEGFR3 (inhibiting tumor blood vessel formation)

  • FGFR1-4, PDGFRα, KIT, RET (inhibiting tumor cell proliferation and survival)

• By blocking these pathways, Lenvatinib reduces angiogenesis and tumor growth, leading to slowed disease progression.

  Uses

  • Treatment of differentiated thyroid cancer (advanced or radioactive iodine-refractory).

  • Treatment of advanced renal cell carcinoma (RCC), usually in combination with everolimus or pembrolizumab.

  • Treatment of hepatocellular carcinoma (HCC) in patients who are not candidates for surgery.

  • Used in unresectable or metastatic tumors to improve progression-free survival.

    Adverse Effects

    • Hypertension (high blood pressure)

    • Fatigue or weakness

    • Diarrhea, nausea, or vomiting

    • Decreased appetite and weight loss